• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy

by | Jun 19, 2024 | Uncategorized

EJHaem. 2024 Apr 30;5(3):485-493. doi: 10.1002/jha2.907. eCollection 2024 Jun. ABSTRACT Belantamab mafodotin is the first-in-class antibody-drug conjugates targeting B-cell maturation antigen to have demonstrated effectiveness in triple-class refractory multiple...

VIDEO: Oral drug regimen well tolerated in older patients with multiple myeloma

by | Jun 18, 2024 | Uncategorized

CHICAGO — In this video, Henry Chi Hang Fung, MD, FACP, FRCPE, spoke with Healio about a study in older patients with relapsed/refractory multiple myeloma.The study was presented at ASCO Annual Meeting and investigated an oral two-drug regimen for frail patients with...

VIDEO: Belantamab mafodotin ‘comeback kid’ for relapsed refractory multiple myeloma

by | Jun 17, 2024 | Uncategorized

CHICAGO — Henry Chi Hang Fung, MD, FACP, FRCPE, spoke with Healio about findings from DREAMM-7 and DREAMM-8— both presented at ASCO Annual Meeting.A previous study assessing belantamab mafodotin monotherapy for the treatment of relapsed refractory multiple myeloma did...

VIDEO: Transplant eligibility may impact treatment options in multiple myeloma

by | Jun 17, 2024 | Uncategorized

CHICAGO — In this video, Henry Chi Hang Fung, MD, FACP, FRCPE, discussed findings assessing the treatment of patients with multiple myeloma who are ineligible for transplant.Fung, chair and professor in the bone marrow transplant and cellular therapies department at...

Multiple Myeloma Progression Still Slowed With Reduced Tecvayli Dosing

by | Jun 17, 2024 | Uncategorized

Source: CureToday articles Data show that patients’ multiple myeloma still fails to progress if patients receive less-frequent Tecvayli. Read More

Moving the Needle With Disparities in Multiple Myeloma

by | Jun 16, 2024 | Uncategorized

Source: CureToday articles Increased awareness and support may be one of the many ways to help decrease the impact of disparities in multiple myeloma. Read More
« Older Entries
Next Entries »

Recent Content

  • Unexpected Support in Tough Times With Multiple Myeloma
  • The AQUILA Debate: Daratumumab and Smoldering Multiple Myeloma
  • Quadruple Therapy With Isatuximab Shows Promise for Older Adults With Multiple Myeloma
  • Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
  • Myeloma cell-derived CXCL7 facilitates proliferation of tumor cells and occurrence of osteolytic lesions through JAK/STAT3 pathway
  • VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target
  • Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia
  • Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma
  • Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention
  • Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT